Minukhina D, Zaikina T, Koteliukh M, Titova G, Zolotaikina V
Kharkiv National Medical University, Ukraine.
Georgian Med News. 2020 Feb(299):70-74.
Aim of study ‒ assess an impact of percutaneous coronary intervention on markers of matrix degradation (MMP-13, TIMP-4) and endothelial-dependent mediators (sVE-cadherin, ADMA) in patients with acute myocardial infarction and diabetes mellitus type 2. 110 patients with AMI were enrolled in the study, 70 patients had concomitant diabetes mellitus type 2. They were additionally divided into two subgroups depending on the treatment (percutaneous coronary intervention or conservative therapy). According to the obtained results, misbalance of extracellular matrix degradation markers (MMP-13, TIMP-4) and endothelial dysfunction (sVE-cadherin, ADMA) were revealed in patients with acute myocardial infarction. Performing of PCI procedure contributes to the significant lowering of MMP-13, sVE-cadherin, ADMA and increasing of TIMP-4 in diabetic patients. It was establishted that performing of percutaneous coronary intervention in patients with acute myocardial infarction and diabetes mellitus type 2 contributes to the maintenance of extracellular matrix that prevents myocardium remodeling and improvement of endothelial function.
研究目的——评估经皮冠状动脉介入治疗对急性心肌梗死合并2型糖尿病患者基质降解标志物（基质金属蛋白酶-13、金属蛋白酶组织抑制因子-4）和内皮依赖性介质（可溶性血管内皮钙黏蛋白、不对称二甲基精氨酸）的影响。110例急性心肌梗死患者纳入研究，其中70例合并2型糖尿病。根据治疗方法（经皮冠状动脉介入治疗或保守治疗），他们被进一步分为两个亚组。根据所得结果，急性心肌梗死患者存在细胞外基质降解标志物（基质金属蛋白酶-13、金属蛋白酶组织抑制因子-4）失衡和内皮功能障碍（可溶性血管内皮钙黏蛋白、不对称二甲基精氨酸）。经皮冠状动脉介入治疗可使糖尿病患者的基质金属蛋白酶-13、可溶性血管内皮钙黏蛋白、不对称二甲基精氨酸显著降低，金属蛋白酶组织抑制因子-4升高。已证实，对急性心肌梗死合并2型糖尿病患者进行经皮冠状动脉介入治疗有助于维持细胞外基质，防止心肌重塑并改善内皮功能。
